Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Ex-US Danyelza Net Product Revenues: $3.1 million in Q3 2024, a 19% decrease from Q3 2023. Total Net Revenue for First Nine Months: $61.2 million, relatively consistent with the same period in 2023. Research and Development Expenses: $11.2 million in Q3 2024, down from $15.4 million in Q3 2023. Selling, General and Administrative Expenses: $13.6 million in Q3 2024, up from $10.2 million in Q3 2023. Net Loss: $7 million in Q3 2024, or negative $0.16 per share, compared to $7.7 million in Q3 2023. Cash and Cash Equivalents: $68.1 million as of the end of Q3 2024, down from $78.6 million at year-end 2023. Full Year 2024 Revenue Guidance: Expected to be in the range of $87 to $95 million, with revenues likely in the bottom half of that range. Warning! GuruFocus has detected 4 Warning Signs with BSP:RAIL3. Release Date: November 08, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Y-mAbs Therapeutics Inc ( NASDAQ:
Show less
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.MarketBeat
- Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
- What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings [Yahoo! Finance]Yahoo! Finance
YMAB
Earnings
- 11/8/24 - Miss
YMAB
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form 10-Q
- YMAB's page on the SEC website